OM:BIOA B
OM:BIOA BBiotechs

BioArctic (OM:BIOA B) Is Up 18.7% After Novartis Partnership and Strong Earnings Turnaround Has The Bull Case Changed?

In late August 2025, BioArctic reported strong second-quarter and half-year results, with sales rising to SEK 392.12 million and SEK 1.68 billion respectively, and moved from a net loss to solid profitability on both periods versus the previous year. Novartis also announced a collaboration and license option agreement with BioArctic for its BrainTransporter technology, offering an upfront US$30 million payment and the potential for further milestone and royalty payments if development...
OM:KBC
OM:KBCChemicals

European Stocks Estimated Below Fair Value In September 2025

As European markets grapple with concerns over U.S. Federal Reserve independence, renewed tariff uncertainties, and political instability in France, the pan-European STOXX Europe 600 Index has seen a notable decline. Amidst these challenges, identifying undervalued stocks becomes crucial for investors seeking opportunities that may be trading below their intrinsic value due to broader market pressures rather than company-specific issues.
OM:HANZA
OM:HANZAElectronic

Exploring Undiscovered Gems in Europe for September 2025

As the European market faces challenges such as renewed tariff uncertainties and political instability, the pan-European STOXX Europe 600 Index has seen a decline, reflecting broader concerns about economic resilience. Despite these headwinds, small-cap stocks often present unique opportunities for investors willing to explore beyond well-trodden paths, particularly in sectors or regions that may benefit from shifting market dynamics and emerging trends.